Core Insights - The probiotic industry is increasingly relying on clinical evidence as a foundation for development, driven by consumer awareness, regulatory standardization, and the demand for genuine product value [1] - The Bifidobacterium animalis subsp. lactis BLa80 strain, isolated from healthy breast milk in China's Sichuan Plateau, has established a comprehensive scientific evidence system and has been officially listed for infant food use [2][4] - BLa80 has successfully passed both self-affirmed GRAS and FDA GRAS certifications, marking it as the first strain in mainland China to achieve dual GRAS status, which enhances the domestic probiotic industry and reduces reliance on imported strains [2][5] Industry Trends - The focus of probiotic research has shifted from broad strain categories to precise validation of specific strain functions, emphasizing the importance of a complete evidence chain from safety assessments to clinical trials and regulatory approvals [8] - The development model of BLa80, which integrates local microbial resources, international and domestic certifications, and comprehensive clinical research covering the entire infant growth cycle, is expected to drive quality improvement and technological advancement in the domestic probiotic industry [8]